2023 World Conference on Lung Cancer (Posters)-P2.10. Characteristics and Outcomes of Hispanic Patients with RET-Fusion Positive NSCLC Treated in Real-World Practice

P2.10. Characteristics and Outcomes of Hispanic Patients with RET-Fusion Positive NSCLC Treated in Real-World Practice - PDF(Abstract)

Back to course

Pdf Summary

This study examined the characteristics and outcomes of Hispanic patients with RET-fusion positive non-small cell lung cancer (NSCLC) treated in real-world practice. RET fusion is a rare genomic alteration in NSCLC, and selective tyrosine kinase inhibitors (TKIs) are available for treatment. However, there is limited data on the use of TKIs in Hispanic patients with RET fusions.<br /><br />The study included 51 patients from five Latin American countries with advanced-stage RET-positive NSCLC. The patients' clinicobiological features and treatment outcomes with various regimens, including chemotherapy, immune checkpoint inhibitors, multikinase inhibitors, and RET-selective inhibitors, were evaluated.<br /><br />The results showed that the most common fusion partner was KIF5B, and the median tumor mutational burden (TMB) was 2 Mt/Mb. PD-L1 expression varied among the patients. In the first-line treatment, the majority of patients received chemotherapy with immune checkpoint inhibitors, while a smaller percentage received multikinase inhibitors or RET-selective inhibitors. The overall response rate to the first-line treatment was 43.5%, and the median progression-free survival was 7.7 months.<br /><br />No significant differences were found in progression-free survival depending on the type of intervention, but those who achieved a partial response had significantly better outcomes. The median overall survival was 30.6 months. In the second-line treatment, targeted therapy with multikinase inhibitors or RET-selective inhibitors showed better progression-free survival compared to chemotherapy or chemotherapy with immune checkpoint inhibitors.<br /><br />The study concluded that Hispanic patients with RET-fusion NSCLC have homogeneous biological behavior. The results of the first-line treatment were consistent with the literature. However, the number of patients treated with RET-selective inhibitors was small, although it showed benefits in overall survival and progression-free survival in the second-line treatment. The study emphasized the need for regional efforts to promote the rapid introduction of RET-selective inhibitors in Latin America.

Asset Subtitle

Oscar Arrieta

Meta Tag

Speaker Oscar Arrieta

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

Hispanic patients

RET-fusion positive non-small cell lung cancer

tyrosine kinase inhibitors

Latin American countries

clinicobiological features

tumor mutational burden

first-line treatment

progression-free survival

overall survival

RET-selective inhibitors